however, differences in injection frequency, dose escalation, and device design meant that investigators were not blinded to which active treatment participants received [1]
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
In simplified terms: BPC-157 research focuses on signaling repair to begin, while TB-500 research focuses on enabling cells to physically reach the repair site
Each signature was queried against the CMap using the algorithm described by Lamb et al .[13]
Related proof pages are linked from the expanded product sections and llms.txt product crawl map
Many international patients specifically travel to Dubai for treatments precisely because of this balance between quality assurance and value